-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
ArriVent BioPharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q4 2024.
- ArriVent BioPharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$20.6M, a 2.64% increase year-over-year.
- ArriVent BioPharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$80.5M, a 16.1% decline year-over-year.
- ArriVent BioPharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$80.5M, a 16.1% decline from 2023.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)